Company / PP&E (Net)
Seres Therapeutics, Inc. PP&E (Net) History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$7.6M
FY2025
5-year range
$7.6M / $23.0M
FY2021-FY2025
Trend
-66.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $23M to $8M over the past 3 years.
Based on SEC 10-K filings.
$8M in FY2025 with a 10-year CAGR of -0.2%.
Declined from $23M to $8M over the past 3 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -30.7%
- 5-Year CAGR
- -11.3%
- 10-Year CAGR
- -0.2%
Key checks
Key Insights
- 5-year CAGR of -11.3%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 66.8% year-over-year.
- Peak pp&e (net) was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.6M | -66.8% |
| FY2023 | $23.0M | +0.0% |
| FY2022 | $23.0M | +28.1% |
| FY2021 | $17.9M | +29.1% |
| FY2020 | $13.9M | -28.7% |
| FY2019 | $19.5M | -25.9% |
| FY2018 | $26.3M | -20.2% |
| FY2017 | $32.9M | -8.8% |
| FY2016 | $36.1M | +366.1% |
| FY2015 | $7.8M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026